首页> 外文期刊>Expert opinion on biological therapy >Secukinumab for treating plaque psoriasis
【24h】

Secukinumab for treating plaque psoriasis

机译:Secukinumab治疗斑块状牛皮癣

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Plaque psoriasis is a chronic inflammatory disease that can result in significant physical, psychological and quality of life impairments. Until recently, biologic treatment for psoriasis was limited to tumor necrosis factor- inhibitors and an interleukin (IL)-12/23 p40 subunit inhibitor. Newly developed biologics targeting the pro-inflammatory IL-17A cytokine have shown success in providing higher levels of clinical efficacy in patients with psoriasis. Secukinumab, a member of this novel class of IL-17 inhibitors, is the latest biologic to receive US FDA approval for the treatment of moderate-to-severe plaque psoriasis.Areas covered: This comprehensive review will cover the pharmacology, efficacy, safety and future role of secukinumab and other IL-17 blockers in the treatment of plaque psoriasis.Expert opinion: While biologics have revolutionized patient care for chronic plaque psoriasis, they are associated with loss of response over time. When treatment failure occurs with existing biologics, physicians are left with few alternative treatment options to offer patients. The introduction of secukinumab has provided an additional therapeutic agent that offers improved skin clearance, better health related quality of life and a favorable side-effect profile.
机译:简介:斑块状牛皮癣是一种慢性炎症性疾病,可能导致严重的身体,心理和生活质量受损。直到最近,牛皮癣的生物治疗仅限于肿瘤坏死因子抑制剂和白介素(IL)-12/23 p40亚基抑制剂。靶向促炎性IL-17A细胞因子的新开发的生物制剂已成功地为牛皮癣患者提供了更高水平的临床疗效。 Secukinumab是这一类新的IL-17抑制剂的成员,是获得美国FDA批准用于治疗中度至重度斑块状牛皮癣的最新生物制剂。涵盖领域:本综述将涵盖药理学,功效,安全性和secukinumab和其他IL-17阻滞剂在斑块状牛皮癣的治疗中的未来作用。专家意见:虽然生物制剂彻底改变了慢性斑块状牛皮癣的患者护理,但它们却随着时间的流逝而失去了反应。当现有生物制剂发生治疗失败时,医生几乎没有其他替代治疗方案可以为患者提供服务。苏金单抗的引入提供了另外的治疗剂,其提供了改善的皮肤清除率,更好的健康相关生活质量和良好的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号